Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.

Lu S, Liu B, Luo Y, Sun L, Wu L, Han Z, Fan Y, Zhao Y, Li X, Xu H, Meng X, Liu Y, Zhang Z, Luo H, Ma X, Ma X, Shi Q, Zhang Z, Yang R, Wang P, Pan P, Ai X, Li J, Pu X, Wang Z, Fang J, He M, He Y, Guo S, Li J, Wang H, Zhang J, Chu Q, Liu X, Ying S, Wu H, Sun H, Ji Y, Zhou M, Cao C, Tang K, Li Z, Li D, Zhang Z, Li J, Zhou J, Yang H, Du Y, Yang H, Shi J, Chen H, Chen Z, Li W, Lu D, Hu M, Wang ZM, Li B, Xia MY

Open source

DOI
10.1016/s0140-6736(26)00966-9
Published
2026 Jun 27
Container
Lancet (London, England)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-00966-9,
  title = {Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.},
  author = {Lu S and Liu B and Luo Y and Sun L and Wu L and Han Z and Fan Y and Zhao Y and Li X and Xu H and Meng X and Liu Y and Zhang Z and Luo H and Ma X and Ma X and Shi Q and Zhang Z and Yang R and Wang P and Pan P and Ai X and Li J and Pu X and Wang Z and Fang J and He M and He Y and Guo S and Li J and Wang H and Zhang J and Chu Q and Liu X and Ying S and Wu H and Sun H and Ji Y and Zhou M and Cao C and Tang K and Li Z and Li D and Zhang Z and Li J and Zhou J and Yang H and Du Y and Yang H and Shi J and Chen H and Chen Z and Li W and Lu D and Hu M and Wang ZM and Li B and Xia MY},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)00966-9},
  url = {https://doi.org/10.1016/s0140-6736(26)00966-9}
}

RIS

TY  - JOUR
TI  - Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.
AU  - Lu S
AU  - Liu B
AU  - Luo Y
AU  - Sun L
AU  - Wu L
AU  - Han Z
AU  - Fan Y
AU  - Zhao Y
AU  - Li X
AU  - Xu H
AU  - Meng X
AU  - Liu Y
AU  - Zhang Z
AU  - Luo H
AU  - Ma X
AU  - Ma X
AU  - Shi Q
AU  - Zhang Z
AU  - Yang R
AU  - Wang P
AU  - Pan P
AU  - Ai X
AU  - Li J
AU  - Pu X
AU  - Wang Z
AU  - Fang J
AU  - He M
AU  - He Y
AU  - Guo S
AU  - Li J
AU  - Wang H
AU  - Zhang J
AU  - Chu Q
AU  - Liu X
AU  - Ying S
AU  - Wu H
AU  - Sun H
AU  - Ji Y
AU  - Zhou M
AU  - Cao C
AU  - Tang K
AU  - Li Z
AU  - Li D
AU  - Zhang Z
AU  - Li J
AU  - Zhou J
AU  - Yang H
AU  - Du Y
AU  - Yang H
AU  - Shi J
AU  - Chen H
AU  - Chen Z
AU  - Li W
AU  - Lu D
AU  - Hu M
AU  - Wang ZM
AU  - Li B
AU  - Xia MY
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)00966-9
UR  - https://doi.org/10.1016/s0140-6736(26)00966-9
ER  -

APA

S, L., B, L., Y, L., L, S., L, W., Z, H., Y, F., Y, Z., X, L., H, X., X, M., Y, L., Z, Z., H, L., X, M., X, M., Q, S., Z, Z., R, Y., P, W., P, P., X, A., J, L., X, P., Z, W., J, F., M, H., Y, H., S, G., J, L., H, W., J, Z., Q, C., X, L., S, Y., H, W., H, S., Y, J., M, Z., C, C., K, T., Z, L., D, L., Z, Z., J, L., J, Z., H, Y., Y, D., H, Y., J, S., H, C., Z, C., W, L., D, L., M, H., ZM, W., B, L., & MY, X. (2026). Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)00966-9

Source records